Loading...
Docoh

Ventyx Biosciences (VTYX)

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.

VTYX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
30 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 45.34M 45.34M 45.34M 45.34M 45.34M
Cash burn (monthly) (no burn) 1.97M 6.8M 6.15M 1.06M
Cash used (since last report) n/a 5.98M 20.64M 18.65M 3.22M
Cash remaining n/a 39.36M 24.71M 26.69M 42.12M
Runway (months of cash) n/a 20.0 3.6 4.3 39.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Aug 22 Christopher W Krueger Common Stock Option exercise Acquire M No No 0.2 72,583 14.52K 352,692
23 Aug 22 Christopher W Krueger Common Stock Option exercise Acquire M No No 0.2 96,778 19.36K 280,109
23 Aug 22 Christopher W Krueger Stock Option Common Stock Option exercise Dispose M No No 0.2 72,583 14.52K 24,195
23 Aug 22 Christopher W Krueger Stock Option Common Stock Option exercise Dispose M No No 0.2 96,778 19.36K 0
9 Jun 22 Gujrathi Sheila Stock Option Common Stock Grant Acquire A No No 16.54 13,301 220K 13,301
9 Jun 22 Richard Gaster Stock Option Common Stock Grant Acquire A No No 16.54 13,301 220K 13,301
9 Jun 22 William Richard White Stock Option Common Stock Grant Acquire A No No 16.54 13,301 220K 13,301
9 Jun 22 Jigar Choksey Stock Option Common Stock Grant Acquire A No No 16.54 13,301 220K 13,301
6.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 64 56 +14.3%
Opened positions 13 52 -75.0%
Closed positions 5 0 NEW
Increased positions 25 1 +2400.0%
Reduced positions 13 0 NEW
13F shares Current Prev Q Change
Total value 518.35M 543.32M -4.6%
Total shares 51.85M 50.46M +2.8%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
NSV Investments I 12.24M $0 0.0%
venBio Global Strategic Fund III 5.01M $95.22M 0.0%
venBio Partners 5.01M $61.29M 0.0%
Third Point 4.31M $52.75M 0.0%
Citadel Advisors 3.89M $47.59M -0.5%
Logos Global Management 2.31M $28.28M -8.0%
Vivo Capital 1.92M $23.5M 0.0%
JHG Janus Henderson 1.91M $23.3M -10.7%
FMR 1.58M $19.27M +92.9%
RTW Investments 1.55M $18.98M 0.0%
Largest transactions Shares Bought/sold Change
FMR 1.58M +758.9K +92.9%
Wellington Management 897.62K -605.35K -40.3%
BLK Blackrock 1.06M +565.85K +115.2%
Vanguard 906.94K +430.08K +90.2%
JHG Janus Henderson 1.91M -228.61K -10.7%
Logos Global Management 2.31M -201.6K -8.0%
Farallon Capital Management 930.65K -183.63K -16.5%
STT State Street 325.34K +154.14K +90.0%
HighTower Advisors 152.58K +152.58K NEW
C Citigroup 124.51K +124.11K +30492.6%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg